505 b(2) application & requirement of bio­equi­va­lence [Regulatives / Guidelines]

posted by Achievwin – US, 2023-05-05 18:08 (147 d 10:46 ago) – Posting: # 23546
Views: 749

Hello Mithu:

505 (b)(2) is all about the submission and marketing strategy. Most of the 505(b)(2) applications take BE route as drug Chemistry, safety and efficacy along with biopharmaceutics is already known and BE is used as a knowledge (claim) gap bridging approach. There are other means you can get 505(b)(2. Please review different guidance (FDA, EMA etc.) or white papers on 505(b)(2).

Hope this helps

Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,627 registered users;
15 visitors (0 registered, 15 guests [including 10 identified bots]).
Forum time: 04:54 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz